Residency · Residency · Vascular Surgery

Raynaud Phenomenon and Vasospastic Disorders

Introduction

Raynaud phenomenon (RP) is an episodic vasospastic disorder characterized by reversible digital ischemia that is typically triggered by cold exposure or emotional stress. The classic presentation involves a triphasic color change in the affected digits: white (pallor) due to arterial vasospasm, followed by blue (cyanosis) reflecting deoxygenation, and finally red (reactive hyperemia) as a result of reperfusion. This condition affects up to 5% of the general population and can be classified as either primary (idiopathic) or secondary to an underlying systemic disease.

Classification

Primary Raynaud Phenomenon (Raynaud Disease)

Primary Raynaud phenomenon is idiopathic, meaning it occurs without any identifiable underlying systemic disease. It typically begins before the age of 30 and shows a strong female predominance, with a ratio of approximately 5:1. The involvement is usually symmetric, affecting both hands equally. Importantly, primary RP does not cause digital ulceration, gangrene, or tissue loss. Nailfold capillaroscopy in these patients is normal, and inflammatory markers such as ESR, CRP, and ANA tests are negative. The course of primary RP is generally benign, with no progression to tissue damage.

Secondary Raynaud Phenomenon

Secondary Raynaud phenomenon occurs in association with an identifiable underlying condition. It often begins after the age of 30 and may present asymmetrically. Secondary RP tends to be more severe and can progress to complications such as digital ulceration, gangrene, and even autoamputation. Nailfold capillaroscopy in these patients reveals abnormalities such as dilated, tortuous, or absent capillaries. Serologic markers are frequently positive, including ANA, anti-centromere antibodies, and anti-Scl-70 antibodies, which help identify specific connective tissue diseases.

Causes of Secondary Raynaud Phenomenon

Secondary RP is commonly associated with connective tissue diseases, with systemic sclerosis (scleroderma) being the most frequent cause. Other connective tissue diseases implicated include systemic lupus erythematosus (SLE), mixed connective tissue disease, dermatomyositis, and rheumatoid arthritis. Arterial occlusive diseases such as atherosclerosis, thromboangiitis obliterans (Buerger disease), and thoracic outlet syndrome can also cause secondary RP. Occupational exposures, including vibration injury (hand-arm vibration syndrome) and hypothenar hammer syndrome, are recognized causes. Hematologic conditions like cryoglobulinemia, cold agglutinin disease, and polycythemia vera contribute as well. Certain medications, including beta-blockers, ergotamines, chemotherapeutic agents such as bleomycin and cisplatin, and amphetamines, may induce or worsen RP.

Pathophysiology

The pathophysiology of Raynaud phenomenon involves an exaggerated contraction of vascular smooth muscle in the digital arteries and arterioles in response to cold or sympathetic nervous system stimulation. Endothelial dysfunction plays a key role, characterized by reduced production of nitric oxide, a vasodilator, and increased levels of endothelin-1, a potent vasoconstrictor. In secondary RP, structural vascular changes such as intimal and adventitial fibrosis and thrombosis are common. Platelet activation and increased blood viscosity further contribute to vascular occlusion in secondary causes. Additionally, dysregulation of the autonomic nervous system, with increased sensitivity of alpha-2 adrenergic receptors, amplifies vasospastic responses.

Diagnostic Evaluation

Clinical Assessment

A thorough clinical assessment begins with a detailed history focusing on the characteristic color changes, their triggers, duration, and progression over time. It is essential to evaluate for symptoms suggestive of connective tissue disease, such as skin thickening, difficulty swallowing (dysphagia), joint pain, and dryness of the eyes and mouth. Occupational and medication histories are important to identify potential secondary causes. The Allen test is performed to assess the completeness of the palmar arch and digital blood flow. Physical examination should include inspection for digital pitting scars, ulcers, or gangrene, which indicate more severe disease.

Laboratory Workup

Laboratory testing includes antinuclear antibody (ANA) screening, which is positive in approximately 95% of patients with scleroderma. Anti-centromere antibodies are associated with limited scleroderma, also known as CREST syndrome, while anti-Scl-70 (anti-topoisomerase I) antibodies are linked to diffuse scleroderma. Additional tests such as erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), complement levels, cryoglobulins, and cold agglutinins help evaluate for systemic inflammation and hematologic causes. A complete blood count is useful to detect polycythemia or thrombocytosis.

Nailfold Capillaroscopy

Nailfold capillaroscopy is a non-invasive technique that examines the capillaries at the base of the fingernails using a dermatoscope or ophthalmoscope. In healthy individuals, the capillaries appear as regular, hairpin-shaped loops. In patients with scleroderma or other connective tissue diseases, the capillaroscopy reveals a characteristic pattern with enlarged, dilated capillaries, hemorrhages, avascular areas, and disorganized capillary architecture. An abnormal nailfold capillaroscopy in a patient with Raynaud phenomenon strongly suggests secondary disease.

Vascular Testing

Vascular testing includes measurement of digital pressures and plethysmography to assess the patency and perfusion of digital arteries. Cold challenge testing with digital pressure monitoring can help confirm the diagnosis. Duplex ultrasound of the upper extremity arteries is useful to exclude proximal arterial disease. When large-vessel involvement is suspected, computed tomography (CT) or magnetic resonance (MR) angiography may be indicated.

Management

Conservative Measures

Management begins with conservative measures such as cold avoidance by wearing insulated gloves and using hand warmers, as well as avoiding cold environments. Smoking cessation is mandatory because nicotine is a potent vasoconstrictor that exacerbates symptoms. Patients should avoid medications that cause vasoconstriction, including beta-blockers, decongestants, and ergots. Stress management and behavioral modification can reduce the frequency of attacks. Protective hand care is important to prevent skin breakdown and secondary infections.

Pharmacologic Therapy

Pharmacologic treatment starts with calcium channel blockers, with nifedipine (30-60 mg daily) being the first-line agent. These drugs reduce the frequency and severity of attacks by 30-50%. Phosphodiesterase-5 inhibitors such as sildenafil (20-50 mg three times daily) are effective, particularly for digital ulcers in scleroderma patients. Topical nitrates, including nitroglycerin paste or patches, can be applied to affected digits to promote vasodilation. Endothelin receptor antagonists like bosentan reduce the formation of new digital ulcers in systemic sclerosis. Prostacyclin analogues, such as intravenous iloprost, are reserved for severe RP with digital ischemia and ulceration due to their potent vasodilatory and platelet-inhibitory effects. Botulinum toxin A injections around the digital arteries have shown promising results in refractory cases by reducing vasospasm.

Surgical Treatment

Surgical options include digital sympathectomy, which involves adventitial stripping of the common and proper digital arteries to relieve vasospasm and improve blood flow. Cervicothoracic (upper dorsal) sympathectomy is rarely performed because of compensatory hyperhidrosis and limited long-term effectiveness but may be considered in severe upper extremity RP. When proximal arterial lesions are identified, bypass or reconstruction procedures, such as subclavian artery stenosis repair or ulnar artery thrombosis correction, may be necessary.

Hypothenar Hammer Syndrome

Hypothenar hammer syndrome results from repetitive trauma to the hypothenar eminence, causing damage to the ulnar artery at the hook of the hamate. It presents with digital ischemia, Raynaud-like symptoms, and ulceration primarily affecting the fourth and fifth digits. Diagnosis is supported by an abnormal Allen test and confirmed by CT angiography, which may reveal ulnar artery aneurysm or occlusion. Treatment involves cessation of the offending activity, antiplatelet therapy, and surgical reconstruction, which may include resection with vein graft interposition or ligation if the palmar arch is complete.

Key Clinical Pearls

Primary Raynaud phenomenon is common and generally benign, not leading to tissue loss, whereas secondary Raynaud phenomenon can progress to digital gangrene and thus requires thorough investigation. Nailfold capillaroscopy is a simple, non-invasive test that effectively distinguishes primary from secondary RP. Testing for anti-centromere and anti-Scl-70 antibodies is essential in all patients suspected of having secondary RP to screen for scleroderma. Calcium channel blockers, particularly nifedipine, are the first-line pharmacologic treatment, with escalation to phosphodiesterase-5 inhibitors, prostacyclins, or botulinum toxin for refractory cases. For severe vasospasm unresponsive to medical therapy, digital sympathectomy offers effective symptom relief.

References

1. Defined, Defined, et al. "Raynaud phenomenon." N Engl J Med. 2016;375(6):556-565.
2. Defined, Defined, et al. "Nailfold capillaroscopy in connective tissue diseases." Best Pract Res Clin Rheumatol. 2013;27(4):437-448.
3. Defined, Defined, et al. "Digital sympathectomy for refractory Raynaud phenomenon." J Vasc Surg. 2016;63(2):459-465.
4. Defined, Defined, et al. "Bosentan for the treatment of digital ulcers in systemic sclerosis (RAPIDS-2)." Ann Rheum Dis. 2011;70(1):32-38.

Read this lecture as Markdown